ClinicalTrials.gg
CompletedNCT00643799CLOAKUpdated Feb 2, 2021

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

A Phase 4 interventional study of Celecoxib and Naproxen in Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 51 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
2nd of 14
586 · median 216
Started
2004
with 2 others
Phase 4
10 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
6 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 2nd largest by enrollment, is one of 3 that started in 2004, is one of 10 in phase 4, and was the 9th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis of the knee as defined by the American College of Rheumatology criteria in a flare state at baseline visit
  • Functional Capacity Classification of I-III

Exclusion criteria

Exclusion Criteria:

  • Inflammatory arthritis or gout/pseudo-gout with an acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Received acetaminophen within 24 hours of the baseline visit
  • Acute joint trauma at index joint within the past 3 months with active symptoms
  • History of gastrointestinal (GI) perforation, obstruction, or bleeding
  • Diagnosed or treated for GI ulcer within 60 days prior to first dose of study medication
  • Received or hyaluronic acid within certain timeframe before study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
586 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Active comparator
    B

    Drug: Naproxen

  • Placebo comparator
    C

    Drug: Placebo

Interventions

  • 200 mg oral capsule once daily for 6 months

  • 500 mg oral capsule twice daily for 6 months

  • DrugPlacebo

    Matched oral placebo for 6 months

06

What researchers measure

Primary outcomes

  1. Number of responders, defined as a 20% improvement from baseline in the The Western Ontario MacMaster (WOMAC)Questionnaire Total Score

    Time frame: Month 6

Secondary outcomes

  1. Number of health care professional contacts

    Time frame: Throughout study

  2. Patient's and Physician's Satisfaction with Current Arthritis Therapy

    Time frame: Month 6

  3. Change in WOMAC Total Score from baseline

    Time frame: Month 6

  4. Change in WOMAC Subscales from baseline

    Time frame: Month 6

  5. Response in each WOMAC Subscale

    Time frame: Month 6

  6. Change in Medical Outcome Study sleep scale from baseline

    Time frame: Month 6

  7. Laboratory tests

    Time frame: Month 6

  8. Vital signs

    Time frame: Month 6

  9. Response in VAS

    Time frame: Month 6

  10. Change in Patient's and Physician's Global Assessment of Pain from baseline

    Time frame: Month 6

  11. Change in visual analog scale (VAS) from baseline

    Time frame: Month 6

  12. Adverse events

    Time frame: Throughout study

  13. Change in Gastrointestinal (GI) Distress Scale from Week 1

    Time frame: Month 6

  14. Change in GI Distress Scale from time of discontinuation of study drug

    Time frame: Month 6

  15. Receipt of prescription or over-the-counter gastroprotective agents or pain medications (off study drug)

    Time frame: Throughout study

  16. Number of hospitalizations, emergency room visits, and procedures

    Time frame: Throughout study

  17. Change in Work Limitation Questionnaire scale scores from baseline

    Time frame: Month 6

  18. Physical examination

    Time frame: Month 6

07

Study locations

51 sites
  • Pfizer Investigational Site
    Montgomery, Alabama 36106, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85014, United States
  • Pfizer Investigational Site
    Tempe, Arizona 85282, United States
  • Pfizer Investigational Site
    Buena Park, California 90620, United States
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92108, United States
  • Pfizer Investigational Site
    Denver, Colorado 80230, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20006, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32204, United States
  • Pfizer Investigational Site
    Miami, Florida 33186, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Orlando, Florida 32804, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    Zephyrhills, Florida 33542, United States
  • Pfizer Investigational Site
    Rockford, Illinois 61103, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67207, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67212, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40503, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40515, United States
  • Pfizer Investigational Site
    Covington, Louisiana 70433, United States
  • Pfizer Investigational Site
    Metairie, Louisiana 70006, United States
  • Pfizer Investigational Site
    Clinton, Maryland 20735, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Hagerstown, Maryland 21740, United States
  • Pfizer Investigational Site
    Wheaton, Maryland 20902, United States
  • Pfizer Investigational Site
    Milford, Massachusetts 01757, United States
  • Pfizer Investigational Site
    Lansing, Michigan 48910, United States
  • Pfizer Investigational Site
    Flowood, Mississippi 39232, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64114, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68506, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68516, United States
  • Pfizer Investigational Site
    New York, New York 10022, United States
  • Pfizer Investigational Site
    Beachwood, Ohio 44122, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43124, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43215, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43222, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Pfizer Investigational Site
    Bethlehem, Pennsylvania 18015, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Media, Pennsylvania 19603, United States
  • Pfizer Investigational Site
    Warwick, Rhode Island 02886, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    San Angelo, Texas 76904, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84109, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84121, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 26, 2008
Start
Mar 2004
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00643799
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Mar 2004
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion